Helical, a pioneering biotech company, is focused on revolutionizing pharmaceutical research and development. With an innovative virtual AI lab, Helical is addressing the critical challenge of limited throughput in physical experimentation during drug discovery. The $10 million seed funding, obtained from major investors including redalpine and tech leaders like Aidan Gomez, is expected to bolster their progress. Founded in early 2024, the company aims to make the drug discovery process more efficient through integration and collaboration across various scientific disciplines.
Helical has become a crucial player in the pharmaceutical industry due to its unique platform, which was previously less focused on computational predictions and biological validation. This innovation contrasts with earlier industry attempts that relied heavily on isolated model outputs. While past efforts emphasized data gathering, Helical presents an interconnected system enhancing direct scientific decision-making.
How Does Helical Tackle the Experimental Bottleneck?
To address challenges in pharmaceutical processes, Helical provides an application layer that combines computational insights with biological validation. The system is designed to create reproducible discovery mechanisms, aiding in the transition from hypothesis to validated scientific findings. This approach reshapes how teams engage with bio foundation models, making operations more cohesive and evidence-based.
What Roles Do Helical’s Virtual Lab and Model Factory Play?
The Virtual Lab and Model Factory, two interconnected components of Helical’s platform, play distinct roles for different specialists. While biologists use the Virtual Lab for experimentation, the Model Factory supports machine learning engineers and data scientists in model development. This synergy facilitates collaborative efforts across varied teams, leveraging shared data and models to expedite drug discovery.
Co-founder Rick Schneider emphasizes the importance of operationalizing insights for meaningful drug discovery, noting the transformative role of their platform.
“Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend.”
He underscores their goal to decrease the time from hypothesis to decision making, stating, “We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months.”
Helical’s collaborations with top global pharmaceutical companies have demonstrated considerable reductions in discovery timelines, broadening the scope of therapeutic designs. Their platform excels in areas like target identification and biomarker discovery, promoting accelerated progress in otherwise time-consuming processes.
With rising costs and longer R&D timelines in the pharmaceutical industry, Helical’s efforts focus on streamlining and increasing drug discovery reliability. They aim to use the newly acquired funds to deepen engagements with current partners and foster relationships with new organizations while improving their platform’s evidence layer.
By making computational and biological science practice more seamless and replicable, Helical represents a significant step forward in biotech innovation. The implications for the drug discovery process are profound, presenting new opportunities for efficiency and accelerated outcomes.
